EUVIMEDEUVIMED entdecken
Crossref

AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

Léna Carmès, Guillaume Bort, François Lux, Léa Seban, Paul Rocchi, Zeinaf Muradova, Agnès Hagège, Laurence Heinrich-Balard, Frédéric Delolme, Virginie Gueguen-Chaignon, Charles Truillet, Stephanie Crowley und 7 weitere

Nanoscale · 2024

DOI: 10.1039/d3nr04777f ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanoscale, 2024. Verfasst von Léna Carmès und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institut Lumière-Matière, UMR 5306, Université Lyon1-CNRS, Université de Lyon, Villeurbanne Cedex 69100, France. francois.lux@univ-lyon1.fr. Hauptthemen laut MEDLINE: Nanoparticles, Neoplasms, Gadolinium. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: Centre National de la Recherche Scientifique, ViewRay.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Comparison of click chemistry and sortagging grafting strategies for functionalizing AGuIX nanoparticles with nanobodies to develop a tri-functional technology combining MRI imaging, radiotherapy, and immunotherapy by inhibiting immune checkpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesNeoplasmsGadoliniumHumansTissue DistributionPrecision Medicine

Substanzen

AGuIXGadolinium

Autor:innen und Institutionen

  • Institut Lumière-Matière, UMR 5306, Université Lyon1-CNRS, Université de Lyon, Villeurbanne Cedex 69100, France. francois.lux@univ-lyon1.fr.
  • NH TherAguix SA, Meylan 38240, France.
  • Institut Curie, PSL Research University, CNRS, UMR9187, INSERM, U1196, Chemistry and Modeling for the Biology of Cancer, F-91400, Orsay, France.
  • Université Paris-Saclay, CNRS, UMR9187, INSERM, U1196, Chemistry and Modeling for the Biology of Cancer, F-91400, Orsay, France.
  • Institut Universitaire de France (IUF), Paris, France.
  • Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston 02115, USA. ross_berbeco@dfci.harvard.edu.

Förderung

  • Centre National de la Recherche Scientifique
  • ViewRay

Zitieren

APA

Carmès, L., Bort, G., Lux, F., Seban, L., Rocchi, P., Muradova, Z., Hagège, A., Heinrich-Balard, L., Delolme, F., Gueguen-Chaignon, V., Truillet, C., Crowley, S., Bello, E., Doussineau, T., Dougan, M., Tillement, O., Schoenfeld, J. D., Brown, N., & Berbeco, R. (2024). AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors. Nanoscale. https://doi.org/10.1039/d3nr04777f

Vancouver

Carmès L, Bort G, Lux F, Seban L, Rocchi P, Muradova Z, et al. AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors. Nanoscale. 2024. doi:10.1039/d3nr04777f

BibTeX
@article{Carms2024,
  author = {Carmès, Léna and Bort, Guillaume and Lux, François and Seban, Léa and Rocchi, Paul and Muradova, Zeinaf and Hagège, Agnès and Heinrich-Balard, Laurence and Delolme, Frédéric and Gueguen-Chaignon, Virginie and Truillet, Charles and Crowley, Stephanie and Bello, Elisa and Doussineau, Tristan and Dougan, Michael and Tillement, Olivier and Schoenfeld, Jonathan D and Brown, Needa and Berbeco, Ross},
  title = {AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors},
  journal = {Nanoscale},
  year = {2024},
  doi = {10.1039/d3nr04777f}
}
Kostenlos starten →